account_id none on file
legal_name Pyxis Oncology, Inc.
ticker PYXS
cik 1782223
domain pyxisoncology.com
linkedin_company_url https://www.linkedin.com/company/pyxis-oncology/
entry_point_account_id none on file
name Pyxis Oncology Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 3 executives 1 family 0
why_nownone on file
callsnone on file
filings
This increase was primarily attributable to a $4.4 million increase in personnel-related expenses, due to an increase in severance costs of $1.2 million and higher stock-based compensation expense of $2.6 million.
filing / Aug 13, 2026 / receipt
Unallocated research and development costs decreased by $2.5 million primarily due to decreased severance expense of $0.9 million, a reduction in other research and development support costs of $0.7 million and decreased employee recruitment costs of $0.6 million.
filing / Aug 13, 2026 / receipt
Unallocated research and development costs decreased by $1.8 million due to decreased severance expense of $1.0 million, decreased employee recruitment costs of $0.4 million, and a reduction in other research and development support costs of $0.4 million.
filing / May 14, 2026 / receipt
executives
| Jitendra Wadhane | Principal Financial Officer | - | receipt |
familynone on file
upcoming
| 2026-11-02 | earnings call | scheduled | ir |
changes
| 2025-07-03 | Principal Financial Officer, appointed | sec_8k |
| 2022-08-09 | Chief Accounting Officer, appointed | sec_8k |
| 2022-04-14 | director, departed | sec_8k |
mcp_package_hint
slug pyxis-oncology-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$